Booming sector received nearly £1.6bn from investors in first eight months of 2018
Biotech is one of the most promising parts of the British drug industry, not least according to the investors who continue to pump vast sums into the sector despite the looming shadow of Brexit. In the first eight months of 2018 alone it received nearly £1.6bn, compared with £1.2bn for the entirety of 2017.
An unassuming building in a science park near the Hertfordshire town of Stevenage is hosting four biotech firms that hope to achieve a major breakthrough for the field – and go some way to justifying that faith from investors.
This post was syndicated from Health | The Guardian. Click here to read the full text on the original website.